Global Inflammatory Bowel Disease Market Research and Forecast 2018-2023
Inflammatory bowel disease (IBD) involves the diseases that cause chronic inflammation of the digestive tract of a human body. The bowel diseases are mainly categorized as Crohn’s disease and Ulcerative colitis. The most probable cause behind such disease is the malfunctioning of immune system or autoimmune disorder leading to damage the healthy cells of digestive tracts. The sedentary life style and the unhealthy food intake is one of the major cause behind the growth of the market. The prevalence of Crohn’s disease and Ulcerative colitis across the world has grown substantially, according to world IBD day a total of 10 million people lives with the disease. The substantial increase in number of patient has also contributed significantly in growth of market. The increased public and private investment in healthcare is propelling the growth in emerging economies. The major factor restraining the growth of the market is high cost of drugs and prolonged treatment tenure. The research and development in novel therapeutics such as stem cell therapy will drive the future market for treatment of IBD.
The market is divided into North America, Europe, Asia Pacific and Rest of the World geographically. North America has the largest market of IBD because of large number of patients in the region, the region also has most advanced healthcare infrastructure. The UK in European region holds the second place in prevalence ranking after the US, the region also has well developed infrastructure for healthcare. The APAC region will grow significantly in coming few years due to increase in expenditure for procurement of better healthcare infrastructure.
The competition in IBD market is tough due to the presence of large number of market player, the market players are engaged in providing anti-inflammatory drugs, R&D in the field of novel therapeutics such as stem cell therapy. The Key Players in the inflammatory bowel disease Abbott Laboratories, Amgen, Inc, AstraZeneca PLC, Baxter International Inc., Bristol-Myers Squibb Company, Cosmo pharmaceuticals, Emory healthcare, F. Hoffmann-La Roche AG, Genfit, Innovate Biopharmaceuticals, Janssen Global Services, LLC, Medanta The Medicity, Mylan Pharmaceuticals Ltd., Novartis AG, Pfizer Inc., Pluristem Therapeutics, Inc., Quest diagnostics. The companies are engaged in rapid research and development for the development of effective treatment measure for the disease.
RESEARCH METHODOLOGY
The market study of Global Inflammatory bowel disease market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases (org, gov and other such websites)
Whitepapers, research-papers and news blogs
Company websites and their product catalogue.
The Report is intended for Researchers in healthcare and pharmaceutical Industry, Emerging IBD drug manufacture, Investing companies, Government Organizations for overall market analysis and competitive analysis. The report provides in-depth analysis on market size, growth opportunity in market, product types. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
MARKET SEGMENTATION:
Global Inflammatory bowel disease Market is segmented on the basis of various regions and below mentioned segments:
Global Inflammatory Bowel Disease Market Research and Analysis, By Disease type
Global Inflammatory Bowel Disease Market Research and Analysis, By Diagnosis method
Global Inflammatory Bowel Disease Market Research and Analysis, By Treatment approach
THE REPORT COVERS:
Comprehensive research methodology of Global Inflammatory Bowel Disease market
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the Global Inflammatory Bowel Disease
Insights about market determinants which are stimulating the Global Inflammatory Bowel Disease
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
The market is divided into North America, Europe, Asia Pacific and Rest of the World geographically. North America has the largest market of IBD because of large number of patients in the region, the region also has most advanced healthcare infrastructure. The UK in European region holds the second place in prevalence ranking after the US, the region also has well developed infrastructure for healthcare. The APAC region will grow significantly in coming few years due to increase in expenditure for procurement of better healthcare infrastructure.
The competition in IBD market is tough due to the presence of large number of market player, the market players are engaged in providing anti-inflammatory drugs, R&D in the field of novel therapeutics such as stem cell therapy. The Key Players in the inflammatory bowel disease Abbott Laboratories, Amgen, Inc, AstraZeneca PLC, Baxter International Inc., Bristol-Myers Squibb Company, Cosmo pharmaceuticals, Emory healthcare, F. Hoffmann-La Roche AG, Genfit, Innovate Biopharmaceuticals, Janssen Global Services, LLC, Medanta The Medicity, Mylan Pharmaceuticals Ltd., Novartis AG, Pfizer Inc., Pluristem Therapeutics, Inc., Quest diagnostics. The companies are engaged in rapid research and development for the development of effective treatment measure for the disease.
RESEARCH METHODOLOGY
The market study of Global Inflammatory bowel disease market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases (org, gov and other such websites)
Whitepapers, research-papers and news blogs
Company websites and their product catalogue.
The Report is intended for Researchers in healthcare and pharmaceutical Industry, Emerging IBD drug manufacture, Investing companies, Government Organizations for overall market analysis and competitive analysis. The report provides in-depth analysis on market size, growth opportunity in market, product types. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
MARKET SEGMENTATION:
Global Inflammatory bowel disease Market is segmented on the basis of various regions and below mentioned segments:
Global Inflammatory Bowel Disease Market Research and Analysis, By Disease type
Global Inflammatory Bowel Disease Market Research and Analysis, By Diagnosis method
Global Inflammatory Bowel Disease Market Research and Analysis, By Treatment approach
THE REPORT COVERS:
Comprehensive research methodology of Global Inflammatory Bowel Disease market
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the Global Inflammatory Bowel Disease
Insights about market determinants which are stimulating the Global Inflammatory Bowel Disease
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATION
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. INDIA
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. UNHEALTHY EATING HABITS AND SEDENTARY LIFESTYLE
3.1.2. RISE IN INCIDENCE OF ULCERATIVE COLITIS AND CROHN’S DISEASE
3.1.3. INCREASING PUBLIC AND PRIVATE INVESTMENT IN HEALTHCARE INFRASTRUCTURE
3.1.4. Increase in Diagnosis rate in developing APAC region
3.2. RESTRAINT
3.2.1. COSTLY DRUGS AND PROLONGED TREATMENT
3.2.2. SIDE EFFECTS ASSOCIATED WITH THE TREATMENT
3.3. OPPORTUNITY
3.3.1. R & D IN STEM CELL THERAPY FOR IBD TREATMENT
3.3.2. ADVANCEMENT IN IMAGING TECHNOLOGIES
4. MARKET SEGMENTATION
4.1. GLOBAL IBD MARKET, BY DISEASE TYPE
4.1.1. ULCERATIVE COLITIS
4.1.2. CROHN’S DISEASE
4.2. GLOBAL IBD MARKET, BY DIAGNOSIS METHOD
4.2.1. BLOOD AND STOOL TESTS
4.2.2. ENDOSCOPIES
4.2.3. ULTRASOUND
4.2.4. X-RAYS
4.3. GLOBAL IBD MARKET, BY TREATMNET APPROACH
4.3.1. SURGERY
4.3.1.1. SURGERY FOR CROHN’S DISEASE
4.3.1.2. SURGERY FOR ULCERATIVE COLITIS
4.3.2. ANTI- INLAMMATORY DRUG ADMINISTRATION
4.3.2.1. STEROIDS
4.3.2.2. IMMUNOSUPPRESSANTS
4.3.2.3. BIOLOGICAL DRUGS
4.3.2.4. AMINOSALICYLATES
4.3.2.5. OTHERS (ANTIBIOTICS, SYMPTOMATIC DRUGS)
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. UK
6.2.2. GERMANY
6.2.3. SPAIN
6.2.4. FRANCE
6.2.5. ITALY
6.2.6. REST OF EUROPE
6.3. APAC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. REST OF APAC
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ACCESA LABS
7.2. AMAG PHARMACEUTICALS
7.3. AMERICAN REGENT, INC
7.4. CSC PHARMACEUTICALS
7.5. DAIICHI SANKYO
7.6. EMISPHERE TECHNOLOGIES INC
7.7. EMPOWER PHARMACY
7.8. ENDO PHARMACEUTICALS INC
7.9. GALENICA
7.10. GLAXOSMITHKLINE
7.11. LABORATORY CORPORATION OF AMERICA® HOLDINGS
7.12. MERCATOR PHARMA
7.13. PANACEA BIOTEC LIMITED
7.14. PHARMACOSMOS
7.15. RPG LIFE SCIENCES LIMITED
7.16. SANOFI
7.17. TAKEDA PHARMACEUTICAL COMPANY LIMITED
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATION
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. INDIA
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. UNHEALTHY EATING HABITS AND SEDENTARY LIFESTYLE
3.1.2. RISE IN INCIDENCE OF ULCERATIVE COLITIS AND CROHN’S DISEASE
3.1.3. INCREASING PUBLIC AND PRIVATE INVESTMENT IN HEALTHCARE INFRASTRUCTURE
3.1.4. Increase in Diagnosis rate in developing APAC region
3.2. RESTRAINT
3.2.1. COSTLY DRUGS AND PROLONGED TREATMENT
3.2.2. SIDE EFFECTS ASSOCIATED WITH THE TREATMENT
3.3. OPPORTUNITY
3.3.1. R & D IN STEM CELL THERAPY FOR IBD TREATMENT
3.3.2. ADVANCEMENT IN IMAGING TECHNOLOGIES
4. MARKET SEGMENTATION
4.1. GLOBAL IBD MARKET, BY DISEASE TYPE
4.1.1. ULCERATIVE COLITIS
4.1.2. CROHN’S DISEASE
4.2. GLOBAL IBD MARKET, BY DIAGNOSIS METHOD
4.2.1. BLOOD AND STOOL TESTS
4.2.2. ENDOSCOPIES
4.2.3. ULTRASOUND
4.2.4. X-RAYS
4.3. GLOBAL IBD MARKET, BY TREATMNET APPROACH
4.3.1. SURGERY
4.3.1.1. SURGERY FOR CROHN’S DISEASE
4.3.1.2. SURGERY FOR ULCERATIVE COLITIS
4.3.2. ANTI- INLAMMATORY DRUG ADMINISTRATION
4.3.2.1. STEROIDS
4.3.2.2. IMMUNOSUPPRESSANTS
4.3.2.3. BIOLOGICAL DRUGS
4.3.2.4. AMINOSALICYLATES
4.3.2.5. OTHERS (ANTIBIOTICS, SYMPTOMATIC DRUGS)
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. UK
6.2.2. GERMANY
6.2.3. SPAIN
6.2.4. FRANCE
6.2.5. ITALY
6.2.6. REST OF EUROPE
6.3. APAC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. REST OF APAC
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ACCESA LABS
7.2. AMAG PHARMACEUTICALS
7.3. AMERICAN REGENT, INC
7.4. CSC PHARMACEUTICALS
7.5. DAIICHI SANKYO
7.6. EMISPHERE TECHNOLOGIES INC
7.7. EMPOWER PHARMACY
7.8. ENDO PHARMACEUTICALS INC
7.9. GALENICA
7.10. GLAXOSMITHKLINE
7.11. LABORATORY CORPORATION OF AMERICA® HOLDINGS
7.12. MERCATOR PHARMA
7.13. PANACEA BIOTEC LIMITED
7.14. PHARMACOSMOS
7.15. RPG LIFE SCIENCES LIMITED
7.16. SANOFI
7.17. TAKEDA PHARMACEUTICAL COMPANY LIMITED
LIST OF TABLES
TABLE 1 GLOBAL IBD MARKET RESEARCH AND ANALYSIS, BY DISEASE TYPE,2017-2023($ MILLION)
TABLE 2 GLOBAL ULCERATIVE COLITIS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 3 GLOBAL CROHN’S DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 4 GLOBAL IBD MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHOD,2017-2023($ MILLION)
TABLE 5 GLOBAL BLOOD AND STOOL TESTS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 6 GLOBAL ENDOSCOPIES MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 7 GLOBAL ULTRASOUND MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 8 GLOBAL X-RAYS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 9 GLOBAL IBD MARKET RESEARCH AND ANALYSIS, BY TREATMENT APPROACH,2017-2023($ MILLION)
TABLE 10 GLOBAL SURGERY MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 11 GLOBAL ANTI-INFLAMMATORY DRUG ADMINISTRATION MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 12 NORTH AMERICA IBD MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023($ MILLION)
TABLE 13 NORTH AMERICA IBD MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023($ MILLION)
TABLE 14 NORTH AMERICA IBD MARKET RESEARCH AND ANALYSIS BY TREATMENT APPROACH, 2017-2023($ MILLION)
TABLE 15 EUROPE IBD MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023($ MILLION)
TABLE 16 EUROPE IBD MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023($ MILLION)
TABLE 17 EUROPE IBD MARKET RESEARCH AND ANALYSIS BY TREATMENT APPROACH, 2017-2023($ MILLION)
TABLE 18 ASIA PACIFIC IBD MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023($ MILLION)
TABLE 19 ASIA PACIFIC IBD MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023($ MILLION)
TABLE 20 ASIA PACIFIC IBD MARKET RESEARCH AND ANALYSIS BY TREATMENT APPROACH, 2017-2023($ MILLION)
TABLE 21 REST OF THE WORLD (ROW) IBD MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 1 GLOBAL IBD MARKET RESEARCH AND ANALYSIS, BY DISEASE TYPE,2017-2023($ MILLION)
TABLE 2 GLOBAL ULCERATIVE COLITIS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 3 GLOBAL CROHN’S DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 4 GLOBAL IBD MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHOD,2017-2023($ MILLION)
TABLE 5 GLOBAL BLOOD AND STOOL TESTS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 6 GLOBAL ENDOSCOPIES MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 7 GLOBAL ULTRASOUND MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 8 GLOBAL X-RAYS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 9 GLOBAL IBD MARKET RESEARCH AND ANALYSIS, BY TREATMENT APPROACH,2017-2023($ MILLION)
TABLE 10 GLOBAL SURGERY MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 11 GLOBAL ANTI-INFLAMMATORY DRUG ADMINISTRATION MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
TABLE 12 NORTH AMERICA IBD MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023($ MILLION)
TABLE 13 NORTH AMERICA IBD MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023($ MILLION)
TABLE 14 NORTH AMERICA IBD MARKET RESEARCH AND ANALYSIS BY TREATMENT APPROACH, 2017-2023($ MILLION)
TABLE 15 EUROPE IBD MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023($ MILLION)
TABLE 16 EUROPE IBD MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023($ MILLION)
TABLE 17 EUROPE IBD MARKET RESEARCH AND ANALYSIS BY TREATMENT APPROACH, 2017-2023($ MILLION)
TABLE 18 ASIA PACIFIC IBD MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2017-2023($ MILLION)
TABLE 19 ASIA PACIFIC IBD MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2017-2023($ MILLION)
TABLE 20 ASIA PACIFIC IBD MARKET RESEARCH AND ANALYSIS BY TREATMENT APPROACH, 2017-2023($ MILLION)
TABLE 21 REST OF THE WORLD (ROW) IBD MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL IBD MARKET SHARE, BY DISEASE TYPE, 2018 VS 2023 (%)
FIGURE 2 GLOBAL IBD MARKET SHARE, BY DIAGNOSIS METHOD, 2018 VS 2023 (%)
FIGURE 3 GLOBAL IBD MARKET SHARE, BY TREATMENT APPROACH, 2018 VS 2023 (%)
FIGURE 4 NORTH AMERICA IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 5 UNITED STATES IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 6 CANADA IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 7 EUROPE IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 8 UK IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 9 GERMANY IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 10 SPAIN IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 11 FRANCE IBDMARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 12 ITALY IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 13 REST OF EUROPE (ROE) IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 14 ASIA PACIFIC IBDMARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 15 INDIA IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 16 CHINA IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 17 JAPAN IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 18 ROAPAC IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 19 REST OF THE WORLD IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
1. ACCESA LABS
2. AMAG PHARMACEUTICALS
3. AMERICAN REGENT, INC
4. CSC PHARMACEUTICALS
5. DAIICHI SANKYO
6. EMISPHERE TECHNOLOGIES INC
7. EMPOWER PHARMACY
8. ENDO PHARMACEUTICALS INC
9. GALENICA
10. GLAXOSMITHKLINE
11. LABORATORY CORPORATION OF AMERICA® HOLDINGS
12. MERCATOR PHARMA
13. PANACEA BIOTEC LIMITED
14. PHARMACOSMOS
15. RPG LIFE SCIENCES LIMITED
16. SANOFI
17. TAKEDA PHARMACEUTICAL COMPANY LIMITED
FIGURE 1 GLOBAL IBD MARKET SHARE, BY DISEASE TYPE, 2018 VS 2023 (%)
FIGURE 2 GLOBAL IBD MARKET SHARE, BY DIAGNOSIS METHOD, 2018 VS 2023 (%)
FIGURE 3 GLOBAL IBD MARKET SHARE, BY TREATMENT APPROACH, 2018 VS 2023 (%)
FIGURE 4 NORTH AMERICA IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 5 UNITED STATES IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 6 CANADA IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 7 EUROPE IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 8 UK IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 9 GERMANY IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 10 SPAIN IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 11 FRANCE IBDMARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 12 ITALY IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 13 REST OF EUROPE (ROE) IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 14 ASIA PACIFIC IBDMARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 15 INDIA IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 16 CHINA IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 17 JAPAN IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 18 ROAPAC IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 19 REST OF THE WORLD IBD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
1. ACCESA LABS
2. AMAG PHARMACEUTICALS
3. AMERICAN REGENT, INC
4. CSC PHARMACEUTICALS
5. DAIICHI SANKYO
6. EMISPHERE TECHNOLOGIES INC
7. EMPOWER PHARMACY
8. ENDO PHARMACEUTICALS INC
9. GALENICA
10. GLAXOSMITHKLINE
11. LABORATORY CORPORATION OF AMERICA® HOLDINGS
12. MERCATOR PHARMA
13. PANACEA BIOTEC LIMITED
14. PHARMACOSMOS
15. RPG LIFE SCIENCES LIMITED
16. SANOFI
17. TAKEDA PHARMACEUTICAL COMPANY LIMITED
